POLRMT
Basic information
Region (hg38): 19:617221-633537
Links
Phenotypes
GenCC
Source:
- combined oxidative phosphorylation deficiency 55 (Strong), mode of inheritance: AR
- combined oxidative phosphorylation deficiency 55 (Limited), mode of inheritance: AD
- combined oxidative phosphorylation deficiency 55 (Limited), mode of inheritance: AR
- combined oxidative phosphorylation deficiency 55 (Limited), mode of inheritance: AD
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Combined oxidative phosphorylation deficiency 55 | AD/AR | Biochemical; Renal | The condition can involve renal and other manifestations, and medical management for this and other manifestations (eg, with elemental phosphorus, calcitriol, and sodium citrate), has been described as benefiical, including related to musculoskeletal sequelae | Biochemical; Musculoskeletal; Neurologic; Renal | 24386581; 33602924 |
ClinVar
This is a list of variants' phenotypes submitted to
- not_specified (293 variants)
- not_provided (56 variants)
- Combined_oxidative_phosphorylation_deficiency_55 (49 variants)
- POLRMT-related_disorder (13 variants)
- Neurodevelopmental_disorder (1 variants)
- Autosomal_dominant_progressive_external_ophthalmoplegia (1 variants)
- Progressive_sclerosing_poliodystrophy (1 variants)
- Long_QT_syndrome (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the POLRMT gene is commonly pathogenic or not. These statistics are base on transcript: NM_000005035.4. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 25 | 29 | ||||
| missense | 288 | 32 | 329 | |||
| nonsense | 6 | |||||
| start loss | 0 | |||||
| frameshift | 2 | |||||
| splice donor/acceptor (+/-2bp) | 3 | |||||
| Total | 9 | 4 | 293 | 57 | 6 |
Highest pathogenic variant AF is 0.000699868
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| POLRMT | protein_coding | protein_coding | ENST00000588649 | 21 | 16375 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 1.74e-20 | 0.448 | 125625 | 0 | 108 | 125733 | 0.000430 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | -1.87 | 933 | 786 | 1.19 | 0.0000567 | 7758 |
| Missense in Polyphen | 301 | 275.09 | 1.0942 | 2690 | ||
| Synonymous | -8.07 | 550 | 356 | 1.54 | 0.0000267 | 2512 |
| Loss of Function | 1.89 | 39 | 54.0 | 0.722 | 0.00000248 | 601 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.000636 | 0.000613 |
| Ashkenazi Jewish | 0.00 | 0.00 |
| East Asian | 0.000502 | 0.000489 |
| Finnish | 0.000125 | 0.0000924 |
| European (Non-Finnish) | 0.000429 | 0.000404 |
| Middle Eastern | 0.000502 | 0.000489 |
| South Asian | 0.00122 | 0.00118 |
| Other | 0.000336 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: DNA-dependent RNA polymerase catalyzes the transcription of mitochondrial DNA into RNA using the four ribonucleoside triphosphates as substrates. {ECO:0000269|PubMed:21278163}.;
- Pathway
- Mitochondrial biogenesis;Mitochondrial Gene Expression;Gene expression (Transcription);Purine metabolism;Pyrimidine metabolism;Mitochondrial transcription initiation;Transcription from mitochondrial promoters
(Consensus)
Recessive Scores
- pRec
- 0.113
Intolerance Scores
- loftool
- 0.770
- rvis_EVS
- -0.02
- rvis_percentile_EVS
- 51.92
Haploinsufficiency Scores
- pHI
- 0.115
- hipred
- N
- hipred_score
- 0.146
- ghis
- 0.502
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- K
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.847
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Polrmt
- Phenotype
- cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cellular phenotype; muscle phenotype;
Gene ontology
- Biological process
- mitochondrial transcription;transcription initiation from mitochondrial promoter;mitochondrion organization
- Cellular component
- mitochondrion;mitochondrial matrix;protein-containing complex;mitochondrial DNA-directed RNA polymerase complex;mitochondrial nucleoid
- Molecular function
- mitochondrial promoter sequence-specific DNA binding;RNA binding;DNA-directed 5'-3' RNA polymerase activity;protein binding;sequence-specific DNA binding